Clinical Rheumatology

, Volume 24, Issue 2, pp 111–116

Soluble adhesion molecules (sVCAM-1, sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 in patients with systemic sclerosis: relationship to organ systemic involvement

  • Anna Kuryliszyn-Moskal
  • Piotr Adrian Klimiuk
  • Stanislaw Sierakowski
Original Article


Systemic sclerosis (SSc) is a chronic, multisystemic, autoimmune disease characterised by vascular changes and varying degrees of fibrosis of the skin and visceral organs. Organ systemic involvement in SSc is associated with an altered function of endothelial cells, perivascular infiltrating mononuclear cells and interstitial fibrosis. To evaluate the relationship between systemic manifestations and immunological markers of endothelial cell activation, serum levels of soluble vascular cell adhesion molecule-1 (sVCAM-1), soluble E-selectin (sE-selectin), vascular endothelial growth factor (VEGF) and endothelin-1 (ET-1) were determined by an enzyme-linked immunosorbent assay in 31 SSc patients and in 30 healthy controls. In comparison with the control group, higher serum concentrations of sVCAM-1, sE-selectin, VEGF and ET-1 were detected in SSc patients (in all cases p<0.001). Elevated concentrations of sVCAM-1 (p<0.05), sE-selectin (p<0.05), VEGF (p<0.05) and ET-1 (p<0.01) dominated in the serum of SSc patients with organ systemic involvement compared to those without systemic manifestation of the disease. These results suggest that the serum levels of sVCAM-1, sE-selectin, VEGF and ET-1 may reflect the extent of internal organ involvement in SSc patients and point to a pathogenic role of these molecules in systemic manifestation of the disease.


sE-selectin sET-1 sVCAM-1 Systemic sclerosis VEGF 



Erythrocyte sedimentation rate




Rheumatoid arthritis


Soluble E-selectin


Systemic sclerosis


Soluble vascular cell adhesion molecule-1


Vascular endothelial growth factor


  1. 1.
    LeRoy EC (1992) Systemic sclerosis. In: McCarty DJ, Koopman WJ (eds) Arthritis and allied conditions, 12th edn. Lea & Febiger, Philadelphia, pp 1293–1299Google Scholar
  2. 2.
    Krishnaswamy G, Kelley J, Yerra L, Smith JK, Chi DS (1999) Human endothelium as a source of multifunctional cytokines: molecular regulation and possible role in human disease. J Interferon Cytokine Res 19:91–104CrossRefPubMedGoogle Scholar
  3. 3.
    Mojcik ChF, Shevach EM (1997) Adhesion molecules. A rheumatologic perspective. Arthritis Rheum 40:991–1004PubMedGoogle Scholar
  4. 4.
    Blann AD, Herrick A, Jayson MIV (1995) Altered levels of soluble adhesion molecules in rheumatoid arthritis, vasculitis and systemic sclerosis. Br J Rheumatol 34:814–819PubMedGoogle Scholar
  5. 5.
    Ho CY, Wong CK, Li EK, Tam LS, Lam CWK (2003) Elevated plasma concentrations of nitric oxide, soluble thrombomodulin and soluble vascular cell adhesion molecule-1 in patients with systemic lupus erythematosus. Rheumatology 42:117–122CrossRefPubMedGoogle Scholar
  6. 6.
    Paleolog EM (1996) Angiogenesis: a critical process in the pathogenesis of RA—a role for VEGF? Br J Rheumatol 35:917–920CrossRefPubMedGoogle Scholar
  7. 7.
    Kikuchi K, Kubo M, Kadono T, Yazawa N, Ihn H, Tamaki K (1998) Serum concentrations of vascular endothelial growth factor in collagen diseases. Br J Dermatol 139:1049–1051CrossRefPubMedGoogle Scholar
  8. 8.
    Harada M, Mitsuyama K, Yoshida H, Sakisaka S, Taniguchi E, Kawaguchi T et al (1998) Vascular endothelial growth factor in patients with rheumatoid arthritis. Scand J Rheumatol 27:377–380CrossRefPubMedGoogle Scholar
  9. 9.
    Lee SS, Joo YS, Kim WU, Min DJ, Min JK, Park SH et al (2001) Vascular endothelial growth factor levels in the serum and synovial fluid of patients with rheumatoid arthritis. Clin Exp Rheumatol 19:321–324PubMedGoogle Scholar
  10. 10.
    Mayes MD (2003) Endothelin and endothelin receptor antagonists in systemic rheumatic disease. Arthritis Rheum 48:1190–1199CrossRefPubMedGoogle Scholar
  11. 11.
    Morelli S, Ferri C, Polettini E, Bellini C, Gualdi GF, Pittoni V et al (1995) Plasma endothelin-1 levels, pulmonary hypertension, and lung fibrosis in patients with systemic sclerosis. Am J Med 99:255–260CrossRefPubMedGoogle Scholar
  12. 12.
    Yamane K, Miyauchi T, Suzuki N, Yuhara T, Akama T, Suzuki H et al (1992) Significance of plasma endothelin-1 levels in patients with systemic sclerosis. J Rheumatol 19:1566–1571PubMedGoogle Scholar
  13. 13.
    Abraham DJ, Vancheeswaran R, Dashwood MR, Rajkumar VS, Pantelides P, Shi-wen X (1997) Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma fibrotic lung disease. Am J Pathol 151:831–841PubMedGoogle Scholar
  14. 14.
    Masi AT, Medsger TA, Rodnan GP et al (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590PubMedGoogle Scholar
  15. 15.
    Steen VD, Powell DL, Medsger TA Jr (1988) Clinical correlations and prognosis based on serum antibodies in patients with systemic sclerosis. Arthritis Rheum 32:196–203Google Scholar
  16. 16.
    Sundy JS, Haynes BF (1995) Pathogenic mechanisms of vessel damage in vasculitis syndromes. Rheum Dis Clin North Am 21:861–881PubMedGoogle Scholar
  17. 17.
    Szekanecz Z, Szegedi G, Koch AE (1998) Angiogenesis in rheumatoid arthritis: pathogenic and clinical significance. J Invest Med 46:27–41Google Scholar
  18. 18.
    Clancy R, Marder G, Martin V, Belmont HM, Abramson SB, Buyon J (2001) Circulating activated endothelial cells in systemic lupus erythematosus. Further evidence for diffuse vasculopathy. Arthritis Rheum 44:1203–1208CrossRefPubMedGoogle Scholar
  19. 19.
    Gruschwitz MS, Hornstein OP, Driesch P (1995) Correlation of soluble adhesion molecules in the peripheral blood of scleroderma patients with their in situ expression and with disease activity. Arthritis Rheum 38:184–189PubMedGoogle Scholar
  20. 20.
    Hebbar M, Lassalle P, Janin A, Vanhee D, Bisiau S, Hatron PY, Tonnel AB, Gosselin B (1995) E-selectin expression in salivary endothelial cells and sera from patients with systemic sclerosis. Arthritis Rheum 38:406–412PubMedGoogle Scholar
  21. 21.
    Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik JP, Cylwik B, Skowronski J, Chwiecko J (2002) Soluble adhesion molecules (ICAM-1, VCAM-1, and E-selectin) and vascular endothelial growth factor (VEGF) in patients with distinct variants of rheumatoid synovitis. Ann Rheum Dis 61:804–809CrossRefPubMedGoogle Scholar
  22. 22.
    Kuryliszyn-Moskal A, Bernacka K, Klimiuk PA (1996) Circulating intercellular adhesion molecule 1 in rheumatoid arthritis—relationship to systemic vasculitis and microvascular injury in nailfold capillary microscopy. Clin Rheumatol 15:367–373PubMedGoogle Scholar
  23. 23.
    Kuryliszyn-Moskal A, Klimiuk PA, Sierakowski S (2001) Serum autoantibodies profile and increased levels of circulating intercellular adhesion molecule-1: a reflection of the immunologically mediated systemic vasculopathy in rheumatic diseases? Arch Immunol Ther Exp 49:423–430Google Scholar
  24. 24.
    Yamane K, Ihn H, Kubo M, Yazawa N, Kikuchi K, Soma Y, Tamaki K (2000) Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma. J Am Acad Dermatol 42:64–69CrossRefPubMedGoogle Scholar
  25. 25.
    Ihn H, Sato S, Fujimoto M, Takehara K, Tamaki K (1998) Increased serum levels of soluble vascular cell adhesion molecule-1 and E-selectin in patients with systemic sclerosis. Br J Rheumatol 37:1188–1192CrossRefPubMedGoogle Scholar
  26. 26.
    Denton CP, Bickerstaff MC, Shiwen XM, Carulli T, Haskard DO, Dubois RM, Black CM (1995) Serial circulating adhesion molecule levels reflect disease activity in systemic sclerosis. Br J Rheumatol 34:1048–1054PubMedGoogle Scholar
  27. 27.
    Ferrara N (1995) Leukocyte adhesion. Missing link in angiogenesis. Nature 376:467CrossRefPubMedGoogle Scholar
  28. 28.
    Apras S, Ertenli I, Ozbalkan Z, Kiraz S, Ozturk MA et al (2003) Effects of oral cyclophosphamide and prednisolone therapy on the endothelial functions and clinical findings in patients with early diffuse systemic sclerosis. Arthritis Rheum 48:2256–2261CrossRefPubMedGoogle Scholar
  29. 29.
    Brenchley PEC (2001) Antagonising angiogenesis in rheumatoid arthritis. Ann Rheum Dis 60: iii71-iii74PubMedGoogle Scholar
  30. 30.
    Koch AE (2003) Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis 62 [Suppl II]:ii60-ii67Google Scholar
  31. 31.
    Tuder RM, Groves B, Badesch DB, Voelkel NF (1994) Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 144:275–285PubMedGoogle Scholar
  32. 32.
    Xu S, Denton CP, Holmes A, Dashwood MR, Abraham DJ, Black CM (1998) Endothelins: effect on matrix biosynthesis and proliferation in normal and scleroderma fibroblasts, J Cardiovasc Pharmacol 31 [Suppl 1]:S360–S363Google Scholar
  33. 33.
    Tabata H, Hara N, Otsuka S, Yamakage A, Yamazaki S, Koibuchi N (2000) Correlation between diffuse pigmentation and keratinocyte-derived endothelin-1 in systemic sclerosis. Int J Dermatol 39:899–902CrossRefPubMedGoogle Scholar
  34. 34.
    Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, Black CM (1994) Circulating endothelin-1 levels in systemic sclerosis subsets—a marker of fibrosis or vascular dysfunction? J Rheumatol 21:1838–1844PubMedGoogle Scholar

Copyright information

© Clinical Rheumatology 2004

Authors and Affiliations

  • Anna Kuryliszyn-Moskal
    • 1
  • Piotr Adrian Klimiuk
    • 1
  • Stanislaw Sierakowski
    • 1
  1. 1.Department of Rheumatology and Internal DiseasesMedical University of BialystokBialystokPoland

Personalised recommendations